Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction

22 Jan 2019

Abstract excerpt

Survival rates for pediatric patients suffering from mixed lineage leukemia (MLL)-rearranged leukemia remain below 50% and more targeted, less toxic therapies are urgently needed. A screening method optimized to discover cytotoxic compounds selective for MLL-rearranged leukemia identified CCI-006 as a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer, Hypoxia, and Metabolism
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30670779
DOI: 10.1038/s41388-018-0666-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunctionPMID 30670779Read ↗

Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemiaSemantic proximity Read ↗

Targeting the mitochondria in acute myeloid leukemiaSemantic proximity Read ↗

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemiaSemantic proximity Read ↗

Mitochondrial metabolism as a target for acute myeloid leukemia treatmentSemantic proximity Read ↗

Mitochondria and Acute Leukemia: A Clinician’s PerspectiveSemantic proximity Read ↗

Mitochondrial abnormalities as a target of intervention in acute myeloid leukemiaSemantic proximity Read ↗

Anisomycin is active in preclinical models of pediatric acute myeloid leukemia via specifically inhibiting mitochondrial respiration.Semantic proximity Read ↗

Inhibition of the succinyl dehydrogenase complex in acute myeloid leukemia leads to a lactate-fuelled respiratory metabolic vulnerability.Semantic proximity Read ↗

A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugsSemantic proximity Read ↗

The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

P422: OMIPALISIB, A DUAL PI3K/MTOR INHIBITOR, TARGETS MITOCHONDRIA AND IMPAIRS OXIDATIVE PHOSPHORYLATION IN ACUTE MYELOID LEUKEMIASemantic proximity Read ↗

Mitochondrial dysfunction fuels drug resistance in adult T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.